Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXKO1L)

• Drug Name: L-796568 Drug Info
• Synonyms: UNII-P50A5YTO0O; L-796568; P50A5YTO0O; CHEMBL111201; AC1MI4YO; L-796568 free base; SCHEMBL1276546; BDBM50092645; N-{4-[2-((R)-2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-4-[3-(4-trifluoromethyl-phenyl)-thiazol-2-yl]-benzenesulfonamide; (R)-N-(4-(2-((2-Hydroxy-2-(pyridin-3-yl)ethyl)amino)ethyl)phenyl)-4-(4-(4-trifluoromethylphenyl)thiazol-2-yl)benzenesulfonamide; (1R)-1-(3-Pyridyl)-2-[4-[[4-[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]phenyl]sulfonylamino]phenethylamino]ethanol

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 3038500
  CAS Number: CAS 211031-01-5
  TTD Drug ID: DMXKO1L

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[3]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[4]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[5]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[6]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[6]
Metoprolol	DMOJ0V6	Acute coronary syndrome	BA41	Approved	[6]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[7]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[8]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[9]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[10]

Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[11]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[12]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[13]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[14]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[8]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[15]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[16]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[17]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[18]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Inhibitor	[2]
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Inhibitor	[2]

References

• [1] Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002 Oct;76(4):780-8.
• [2] Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9.
• [3] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [4] Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
• [5] Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
• [6] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [7] Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
• [8] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [9] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [10] beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
• [11] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [12] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [13] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [14] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [15] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [16] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [18] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [19] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.